Results 61 to 70 of about 4,258 (204)

Evaluation of Sustained Disease Control With Nipocalimab Versus Placebo in the Phase 3 Vivacity‐MG3 Study

European Journal of Neurology, Volume 33, Issue 5, May 2026.
In the Vivacity‐MG3 study, clinical response to nipocalimab was assessed using the MG‐ADL and QMG measures. Nipocalimab treatment improves gMG symptoms earlier than placebo and provides sustained disease control over the 24‐week double‐blind period.
Tuan Vu, Said R. Beydoun, Richard J. Nowak, Hans Katzberg, Maria Ait‐Tihyaty, Kavita Gandhi, John J. Sheehan, Sheryl Pease, Ibrahim Turkoz, Bernie Sattin, Zia Choudhry, Sindhu Ramchandren, Carlo Antozzi   +12 more
wiley   +1 more source

Sepsis Management in a Case of Myasthenic Crisis: A Case Report

Archives of Anesthesia and Critical Care
Myasthenic crisis can affect the respiratory muscles in a life-limiting way that requires intubation and mechanical ventilation. This is a case report of a myasthenic crisis in a 61-year-old woman that became complicated following a lack of response to ...
Hossein Karballaei Mirzahosseini, Ehsan Yousefi-Mazhin, Rezvan Hassanpour, Atabak Najafi, Mahsa Tofighi-Mohammadi, Hamidreza Sharifnia, Amirmahdi Mojtahedzadeh, Mojtaba Mojtahedzadeh   +7 more
doaj   +1 more source

Distinguishing Myasthenia Exacerbation from Severe Preeclampsia: A Diagnostic and Therapeutic Challenge [PDF]

Journal of Clinical and Diagnostic Research, 2015
Myasthenia gravis is an acquired, autoimmune neuromuscular disorder characterized by voluntary muscle weakness. Pregnant patients may have disease exacerbation, respiratory failure, crisis, adverse drug reaction, surprisingly enough remission at any ...
Pooja Sikka, Bharti Joshi, Neelam Aggarwal, Vanita Suri, Hement Bhagat   +4 more
doaj   +1 more source

Prediction of Myasthenia Gravis Worsening: A Machine Learning Algorithm Using Wearables and Patient‐Reported Measures

Annals of Clinical and Translational Neurology, Volume 13, Issue 4, Page 714-723, April 2026.
ABSTRACT Background Myasthenia gravis (MG) is a rare disorder characterized by fluctuating muscle weakness with potential life‐threatening crises. Timely interventions may be delayed by limited access to care and fragmented documentation. Our objective was to develop predictive algorithms for MG deterioration using multimodal telemedicine data ...
Maike Stein, Haoqi Sun, Sophie Lehnerer, Lea Gerischer, Maximilian Mönch, Christian Meisel, Andreas Meisel, Pushpa Narayanaswami   +7 more
wiley   +1 more source

Thirteen years follow-up after radical transsternal thymectomy for myasthenia gravis. Do short-term results predict long-term outcome? [PDF]

, 2017
Objective: Long-term evaluation of efficacy and quality of life after radical surgical approach for myasthenia gravis (MG). Comparison between short-term follow-up and long-term outcome.
Ackermann, R., Inderbitzi, R., RoslerRösler, K., Roth, T., Schmid, R.A., Stein, R.   +5 more
core  

Autoantibodies to Agrin in Myasthenia Gravis Patients [PDF]

, 2014
To determine if patients with myasthenia gravis (MG) have antibodies to agrin, a proteoglycan released by motor neurons and is critical for neuromuscular junction (NMJ) formation, we collected serum samples from 93 patients with MG with known status of ...
A Aharonov, A Alshekhlee, A Pevzner, A Vincent, A Vincent, AG Engel, AG Engel, AG Engel, AR Punga, AS Carr, B Zhang, B Zhang, B Zhang, Beverly Bealmear, BG Wallace, Bin Zhang, C Shen, Chengyong Shen, CM Gomez, D Lavrnic, DB Drachman, DB Sanders, DJ Glass, DP Richman, EW Godfrey, H Suhail, H Wu, H Wu, I Kao, J Cossins, J McConville, J Patrick, JM Lindstrom, JM Lindstrom, JM Lindstrom, JR Fallon, JR Fallon, JR Sanes, JR Sanes, JT Campanelli, JY Kim, K Shigemoto, L Zhou, LH Phillips Jr, Lin Mei, M Gautam, M Gesemann, MA Ruegg, MI Leite, MJ Ferns, MN Meriggioli, Mohammed Akaaboune, N Kim, O Higuchi, P Christadoss, P Tsiamalos, Richard A. Lewis, RL Rotundo, RN Cole, Robert P. Lisak, S Jha, S Luo, Samia Ragheb, SC Froehner, SD Weatherbee, TM DeChiara, UJ McMahan, UJ McMahan, V Kumar, W Hoch, W Lin, Wen-Cheng Xiong, WP ter Beek, X Yang, Z Luo   +74 more
core   +3 more sources

Decades of Misdiagnosis as Myasthenia Gravis: Late‐Onset POLG‐Related Ophthalmoplegia Unveiled by Whole‐Genome Sequencing

Clinical Case Reports, Volume 14, Issue 4, April 2026.
ABSTRACT A 55‐year‐old male developed POLG‐related ophthalmoplegia in 2015 and was misdiagnosed with seronegative myasthenia gravis for 10 years. Whole‐genome sequencing identified compound heterozygous POLG mutations, highlighting its value in diagnosing refractory neuromuscular disorders.
Tanli Lu, Huadong Lv, Xiaodan Luo, Xiuying Liu   +3 more
wiley   +1 more source

Effective Early Treatment of AChR Antibody-Positive Myasthenia Gravis with Rituximab; the Experience from a Neuroimmunology Clinic in a Developing Country

Journal of Central Nervous System Disease, 2021
Background: Rituximab is reserved for treating refractory myasthenia gravis (MG) patients. Here we report our experience with rituximab in AChR antibody positive generalized MG (gMG) and impending myasthenic crisis (IMC).
Thomas Mathew, Kurian Thomas, Saji K John, Shruthi Venkatesh, Raghunandan Nadig, Sagar Badachi, Delon D Souza, GRK Sarma, Gareth J Parry   +8 more
doaj   +1 more source

Patients With Myasthenia Gravis With Acute Onset of Dyspnea: Predictors of Progression to Myasthenic Crisis and Prognosis

Frontiers in Neurology, 2021
Background: Life-threatening myasthenic crisis (MC) occurs in 10–20% of the patients with myasthenia gravis (MG). It is important to identify the predictors of progression to MC and prognosis in the patients with MG with acute exacerbations.Objective ...
Yangyu Huang, Ying Tan, Jiayu Shi, Ke Li, Jingwen Yan, Yuzhou Guan   +5 more
doaj   +1 more source

PharmVar GeneFocus: NAT2—Genetic Variation and Updated Nomenclature

Clinical Pharmacology &Therapeutics, Volume 119, Issue 4, Page 859-871, April 2026.
The Pharmacogene Variation Consortium (PharmVar) provides nomenclature for the highly polymorphic human N‐acetyltransferase 2 (NAT2) gene. NAT2 metabolizes several clinically used drugs including isoniazid, hydralazine, amifampridine, procainamide, and sulfonamides such as dapsone, and also some highly carcinogenic arylamines.
Georgia Papanikolaou, Estella S. Poloni, José A.G. Agúndez, Raquel L.F. Teixeira, Erin C. Boone, Adalberto Rezende Santos, Michelle Whirl‐Carrillo, Katrin Sangkuhl, Teri E. Klein, Mariam R. Habil, Giannoulis Fakis, Rodney F. Minchin, David W. Hein, Sotiria Boukouvala, Andrea Gaedigk   +14 more
wiley   +1 more source